Arbutus has moved into Part 3 of this clinical trial which evaluates repeat dosing of AB-101 for 28 days in patients with cHBV and expects to report preliminary data in the first half of next year.
Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14% on an operational basis due to ...
18h
Pfizer and Moderna are hustling to develop an mRNA bird flu vaccine, the same technology used in the companies' respective COVID-19 vaccines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback